for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cansino Biologics Inc

688185.SS

Latest Trade

288.14CNY

Change

-11.89(-3.96%)

Volume

2,179,987

Today's Range

287.21

 - 

300.02

52 Week Range

235.71

 - 

798.00

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
300.03
Open
300.00
Volume
2,179,987
3M AVG Volume
54.75
Today's High
300.02
Today's Low
287.21
52 Week High
798.00
52 Week Low
235.71
Shares Out (MIL)
230.73
Market Cap (MIL)
53,469.16
Forward P/E
25.74
Dividend (Yield %)
--

Next Event

Q4 2021 CanSino Biologics Inc Earnings Release

Latest Developments

More

JPMorgan Chase & Co's Long Position In CanSino Biologics Falls To 9.92% - HKEX Filing

Capital Group Companies Inc's Long Position In Cansino Biologics Rises To 23.0% - HKEX Filing

Capital Group Companies Inc's Long Position In Cansino Biologics Falls To 22.85% - Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cansino Biologics Inc

CanSino Biologics Inc is a clinical-stage vaccine company in China. The Company's products include Ad5-EBOV vaccine used for Ebola virus, MCV2 and MCV4 vaccines for meningococcus, PBPV vaccine used for pneumococcal and the recombinant novel coronavirus vaccine. Its products are mainly used in meningitis, diphtheria pertussis tetanus (DPT) and pneumonia.

Industry

Biotechnology & Drugs

Contact Info

+86.22.58213766

http://www.cansinotech.com.cn/

Executive Leadership

Xuefeng Yu

Executive Chairman of the Board, Chief Executive Officer, General Manager

Luo Xi

Chief Financial Officer

Shou Bai Chao

Chief Operating Officer, Deputy General Manager, Executive Director

Dongxu Qiu

Executive Vice President, Deputy General Manager, Executive Director

Huihua Mao

Executive Vice President, Deputy General Manager

Key Stats

1.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2020

0.0K

2021(E)

6.6K
EPS (CNY)

2020

-1.720

2021(E)

11.196
Price To Earnings (TTM)
66.83
Price To Sales (TTM)
17.22
Price To Book (MRQ)
9.33
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
15.80
LT Debt To Equity (MRQ)
2.74
Return on Investment (TTM)
15.59
Return on Equity (TTM)
12.69

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up